|
BioScreening - organic compounds for screening
Medicinal Chemistry NewsPotent Novel Tool For Combating Autoimmune Diseases And Leukemia - A study carried out by the scientists at the Scripps Research Institute illustrated a novel, highly practical strategy for identifying molecules that avert a particular form of immune cells from launching assaults on their host. These findings have added a potent new-fangled tool to the ongoing investigation for probable treatments [...]
3rd International Symposium on Advances in Synthetic and Medicinal Chemistry - Kiev, Ukraine, August 23 - 27, 2009
ASMC09 in Kiev is being prepared by EFMC (European Federation for Medicinal Chemistry) and ChemBridge Corporation, in the series of events which started with ASCMC04 Moscow followed by ASMC07 St. Petersburg.
Prof. Erick Carreira, ETH Zurich, Switzerland and Dr Scott Biller, Novartis Institutes for BioMedical Research, Cambridge, USA, have kindly [...]
KINAXO’s Cellular Target Profiling® reveals mTOR as a new target of Celebrex - Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis [...]
Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease - Hamburg, Germany and Stockholm, Sweden, January 21st, 2009 — Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera’s novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended [...]
International symposium “Stem Cell Transplantation in Multiple Sclerosis, October 5th, 2009 Moscow, Russia - International symposium “Stem Cell Transplantation in Multiple Sclerosis: Sharing the Experience” will be held on October 5th, 2009 in Moscow, Russia. Symposuim Organizers are Pirogov National Medical Surgical Center, National Center for Research and Treatment of Autoimmune Diseases, Russian Cooperative Group for Cellular Therapy, New Jersey Center for Quality of Life and Health Outcomes Research.
The [...]
Vanderbilt University Announces Partnership with Janssen Pharmaceutica N.V. for Schizophrenia Drug Research - Vanderbilt University is pleased to announce a licensing and research agreement with Janssen Pharmaceutica N.V., focusing on discovery of novel drugs for the treatment of schizophrenia. Under the terms of the agreement Vanderbilt University grants Janssen Pharmaceutica N.V. a worldwide exclusive license to existing compounds acting on a neurotransmitter receptor target, and provides a mechanism [...]
CytRx Unveils Clinical Development Plan for Pipeline Assets - Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor
LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug [...]
MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease
The difficulties of Cushing’s syndrome
GEN Reports on the Trend Toward Predictive Toxicogenomics - NEW ROCHELLE, N.Y., Nov 19, 2008 /PRNewswire via COMTEX/ — Biotech scientists increasingly are applying genomics technologies to toxicology research to better understand the effects of novel drug candidates on a variety of organ systems, reports Genetic Engineering & Biotechnology News (GEN). They are especially interested in figuring out a new compound’s mechanism of action [...]
WuXi PharmaTech Inks New Three-year Deal with Pfizer - WuXi PharmaTech (NYSE: WX) has signed a new three-year CRO deal with Pfizer (NYSE: PFE) to collaborate on in vitro ADME (Absorption, Distribution, Metabolism and Excretion) services. Although WuXi has already been providing the services to Pfizer, WuXi said the new agreement “strengthens an already productive relationship.” WuXi also provides Pfizer with synthetic chemistry, parallel [...]
Drug Discovery Latin America, February 26-27, 2009 - Rio de Janeiro, Brazil - The inaugural Drug Discovery Latin America conference and exhibition will be held in the colourful city of Rio de Janeiro in the days immediately following the world famous carnival.
The purpose of this meeting is to review the status of drug discovery activities in Latin America and to assist its future development. Business and research leaders [...]
BNC Collaborators Author High-profile Paper in Nature Nanotechnology - London, UK – 17 October 2008: Research by scientists collaborating with specialist product development consultancy, Bio Nano Consulting (BNC), into the workings of vancomycin - one of the few antibiotics that can be used to combat increasingly resistant infections such as MRSA - has been published in Nature Nanotechnology (October 2008). The researchers, led by [...]
Cell-Based Assays: Innovations in Reagents, Technologies & Screening October 23 - 24, 2008 - Cell-based assays provide one of the most valuable tools in drug discovery. They are routinely used in target validation, HTS campaigns, structure activity relationship analyses and ADMET studies. Many factors need to be considered in designing, developing and running relevant cell based assays to progress discovery programs. Significant advances continue to be made in assay [...]
Improving Solubility 2008 October 27-29, 2008 Philadelphia, PA - This year’s Improving Solubility conference is essential for scientists working with poorly soluble drugs. With the increased number of poorly soluble drugs coming to the market, expansion of pipelines, effective research investment, and the incorporation of the correct strategy, it is vital for scientists working with poorly soluble drugs to ensure that they have the [...]
XXth International Symposium on Medicinal Chemistry - Vienna, Austria, August 31 - September 4, 2008
This symposium is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance, which varies between 1200 and 1500 participants from all over Europe, but also from the United States and Asia.
The Symposium will focus on important new scientific and technological [...]
Idealp-Pharma launches « hit-to-candidate » services - Services to accelerate programs from biological target to first-in-man use Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics,
screening, early ADMET and preclinical development capabilities to speed up
partner’s and client’s small molecules programs from biological target to firstin-
man use.
According to Serge Petit, PhD, President and CEO, “Being a one-stop-shop [...]
4th Annual International Conference on Compound Libraries - in Dusseldorf, Germany from 6th to 8th October 2008. - From Focused Compound Libraries to optimised Hit-to-Lead - that’s the motto of IQPC’s 4th international conference on “Compound Libraries” (formerly “Focused Compound Libraries”). Nowadays the pharmaceutical industry is under enormous pressure, and the key for the industry to survive is faster and more efficient drug discovery. To improve their lead generation process and library, pharmaceutical [...]
Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe - Carlsbad, Calif., and Beltsville, Md., May 7, 2008 – In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated tissue samples [...]
Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec - Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new drug discovery agreement targeting a protease chosen by Ono.
The collaboration applies Evotec’s proprietary fragment-based drug discovery platform, EVOlutionTM to identify novel, small molecular weight compounds active against a [...]
Links
|
|
